Degron Therapeutics builds molecular glue degrader medicines via its proprietary GlueXplorer® discovery platform, which has generated more than 10,000 structurally differentiated MGD compounds across over 150 novel non-IMiDs cores. Its lead program, DEG6498, is a first-in-class HuR molecular glue degrader that entered a Phase 1 first-in-human study with first patient dosed in November 2025 and has IND clearances in the U.S. and China. The company’s pipeline spans oncology, inflammation, metabolic disorders, and rare diseases, and includes two immunology programs being advanced toward development candidate/IND stage in 2026. Degron was founded in 2021 and is headquartered in Shanghai, with offices in Hangzhou and San Diego. The company has partnered with external pharmaceutical companies, including Takeda, to expand MGD R&D.

Total raised

$62M

Funding rounds

3

Latest round

Series A

Latest activity

May 2026